Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients - PERMAL study subset analysis

European Urology

Volumn 45, Issue 6, 2004, Pages 773-780

  Debruyne, Frans ^a   Boyle, Peter ^b   Calais Da Silva, Fernando ^c   Gillenwater, Jay G ^d   Hamdy, Freddie C ^e   Perrin, Paul ^f   Teillac, Pierre ^g   Vela Navarrete, Remigio ^h   Raynaud, Jean Pierre ⁱ   Schulman, Claude C ^j  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Grupo Portugues Genito Urinario   (Portugal)

^d UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f Antiquaille Hospital   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j ERASME HOSPITAL   (Belgium)

more..

Author keywords

blockers; BPH; Permixon; Phytotherapy; Serenoa repens; Tamsulosin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; SABAL EXTRACT; TAMSULOSIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EJACULATION DISORDER; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SABAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINARY TRACT OBSTRUCTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANDROGEN ANTAGONISTS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA; SEVERITY OF ILLNESS INDEX; SULFONAMIDES;

EID: 2442602361     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.01.015     Document Type: Article

References (30)

1. Holtgrewe H.L. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology. 51(Suppl 4A):1998;1-7
2. Oesterling J.E. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N. Engl. J. Med. 332:1995;99-109
3. Buck A.C. Phytotherapy for the prostate. Br. J. Urol. 78:1996;325-336
4. Wilt T.J., Ishani A., Stark G., MacDonald R., Lau J., Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 280(18):1998;1604-1609
5. Lowe F.C., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology. 53(4):1999;671-678
6. Chacon A., Monga M. Medical management of benign prostatic hyperplasia. Geriatr. Nephrol. Urol. 9(1):1999;39-48
7. Clifford G.M., Farmer R.D. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur. Urol. 38(1):2000;2-19
8. Champault G., Patel J.C., Bonnard A.M. A double-blind trial of an extract of the plant Serenoa Repens in benign prostatic hypertrophy. Br. J. Clin. Pharmacol. 18(3):1984;461-462
9. Tasca A., Barulli M., Cavazzana A., Zattoni F., Artibani W., Pagano F. Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo. Minerva. Urol. Nefrol. 37(1):1985;87-91
10. ® versus placebo: results of a multicentre study. C. R. Ther. Pharmacol. Clin. 4:1985;15-21
11. ® in benign prostatic hyperplasia after exclusion of placebo responders. Clin. Drug Invest. 9:1995;291-297
12. Boyle P., Robertson C., Lowe F., Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology. 55(4):2000;533-539
13. ®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1, 098 patients. Prostate. 29(4):1996;231-240
14. Debruyne F., Koch G., Boyle P., Calais Da Silva F., Gillenwater J.G., Hamdy F.C., et al. for the members of the PERMAL Study Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur. Urol. 41:2002;497-507
15. Saw palmetto. Rockville (MD): Pharmacopeial Convention, 2002.
16. Gerber G.S. Saw palmetto for the treatment of men with lower urinary tract symptoms. J. Urol. 163:2000;1408-1412
17. Barry M.J., Fowler F.J., O'Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol. 148(5):1992;1549-1557
18. Witjes W.P., de la Rosette J.J., Zerbib M., et al. Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flow. Eur. Urol. 33(1):1998;54-63
19. Marquis P., Marrel A. Reproducibility and clinical concurrent validity of the MSF-4: A four item male sexual function questionnaire for patients with benign prostatic hyperplasia. Value in Health. 4(4):2001;335-343
20. Terris M.K., Stamey T.A. Determination of prostate volume by transrectal ultrasound. J. Urol. 145:1991;984-987
21. Denis L, Griffiths S, Khoury ATK, et al. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Paris, July 2-5, 1997. pp. 439-91.
22. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 51(6):1998a;901-906
23. Brooks S.K. Effect of tamsulosin on AUA symptom score and BPH impact index as a function of symptom severity in patients with benign prostatic hyperplasia. J. Urol. 161(Suppl.):1999;267
24. De Mey C. α1-Blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials? Eur. Urol. 38(Suppl. 1):2000;25-39
25. Schulman C.C., Cortvriend J., Jonas U., Lock T.M., Vaage S., Speakman M.J. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur. Urol. 36(6):1999;609-620
26. Veltri R.W., Marks L.S., Miller M.C., et al. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: Evidence for a possible molecular mechanism. Urology. 60(4):2002;617-622
27. Debruyne F., Koch G., Boyle P., Calais Da Silva F., Gillenwater J.G., Hamdy F.C., et al. for the members of the PERMAL study. Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur. Urol. 41(5):2002;497-507
28. Carraro J.C., Raynaud J.P., Koch G., et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1, 098 patients. Prostate. 29(4):1996;231-240
29. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, Ltd.; 2003.
30. Begg C.B., Cho M.K., Eastwood S., et al. Improving the quality of reporting of randomised controlled trials: the CONSORT statement. JAMA. 276:1996;637-639